Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma

PURPOSE: Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase II trials have reported variable outcomes. Vascular endothelial growth factor (VEGF) inhibitors have activity against MM in preclinical models. We added the anti-VEGF antibody bevacizumab to gemci...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kindler, Hedy L., Karrison, Theodore G., Gandara, David R., Lu, Charles, Krug, Lee M., Stevenson, James P., Jänne, Pasi A., Quinn, David I., Koczywas, Marianna N., Brahmer, Julie R., Albain, Kathy S., Taber, David A., Armato, Samuel G., Vogelzang, Nicholas J., Chen, Helen X., Stadler, Walter M., Vokes, Everett E.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2012
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397785/
https://ncbi.nlm.nih.gov/pubmed/22665541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.5869
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items